JAK2 and neoplasm: Methylation of the HOXC10 promoter, resulting in transcriptional repression, has been shown to contribute to resistance to endocrine therapy in estrogen receptor-positive breast cancer (Pathiraja et al., 2014) In addition, studies have demonstrated that HOXC10 can promote tumor growth in BRCA by upregulating the level of IL-6 to activate the JAK2/STAT3 signal transduction pathway (Shen et al., 2022).